Athersys to Host Third Quarter Financial Results Call
Athersys, Inc. (Nasdaq: ATHX) is set to announce its third quarter 2020 financial results on November 9, 2020, at 4:00 PM Eastern Time, followed by a conference call at 4:30 PM. Shareholders can participate in the call via a webcast or phone registration. A replay will be available shortly after the event on the company’s website until November 16, 2020. Athersys focuses on developing therapeutic product candidates, particularly the MultiStem® cell therapy, targeting various diseases. The call aims to provide insights into financial performance and ongoing clinical trials.
- Scheduled release of third quarter 2020 financial results on November 9, 2020.
- Engaged in the development of MultiStem® cell therapy, targeting critical health indications.
- None.
CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX) will release its third quarter 2020 financial results at approximately 4:00 PM Eastern Time on Monday, November 9, 2020, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows:
Date |
November 9, 2020 |
Time |
4:30 p.m. (Eastern Time) |
Live webcast registration |
|
Phone registration |
We encourage shareholders to listen using the webcast link above. If you would like to dial in using the phone to ask a question, please register for the conference call ahead of time using the call registration link above. Once registered, you will receive the toll-free number, a direct entry passcode and a registrant ID. A reminder email will be sent the day before the live call with the above details.
A replay of the event will be available on the webcast link at www.athersys.com under the investors section approximately three hours after the call has ended. Shareholders may also call in for on-demand listening approximately three hours after the completion of the call until 11:59 PM Eastern Time on November 16, 2020 by dialing (800) 585-8367 or (416) 621-4642 and entering the conference code 8465606.
About Athersys
Athersys is a biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the neurological, inflammatory and immune, cardiovascular and other critical care indications and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and a broad network of collaborations to further advance the MultiStem cell therapy toward commercialization. More information is available at www.athersys.com. Follow Athersys on Twitter at www.twitter.com/athersys.
